Alnylam Pharmaceuticals, Inc. revenue breakdown overview

Alnylam Pharmaceuticals, Inc. revenue for the last year amounted to 1.83 B USD, the most of which — 1.83 B USD — came from its highest performing source at the moment, Ribonucleic Acid Interference Therapeutics, the year earlier bringing 1.04 B USD. The greatest contribution to the revenue figure was made by United States — last year it brought Alnylam Pharmaceuticals, Inc. 1.28 B USD, and the year before that — 615.72 M USD.